156 related articles for article (PubMed ID: 37782562)
1. The assessment of tumor-infiltrating lymphocytes in invasive apocrine carcinoma of the breast in relation to the HER2 status.
Gatalica Z; Kuzmova N; Rose I; Ulamec M; Peric-Balja M; Skenderi F; Vranic S
Biomol Biomed; 2024 Mar; 24(2):256-261. PubMed ID: 37782562
[TBL] [Abstract][Full Text] [Related]
2. CD8(+) tumor-infiltrating lymphocytes contribute to spontaneous "healing" in HER2-positive ductal carcinoma in situ.
Morita M; Yamaguchi R; Tanaka M; Tse GM; Yamaguchi M; Kanomata N; Naito Y; Akiba J; Hattori S; Minami S; Eguchi S; Yano H
Cancer Med; 2016 Jul; 5(7):1607-18. PubMed ID: 27061242
[TBL] [Abstract][Full Text] [Related]
3. Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers.
Watanabe T; Hida AI; Inoue N; Imamura M; Fujimoto Y; Akazawa K; Hirota S; Miyoshi Y
Breast Cancer Res Treat; 2018 Feb; 168(1):135-145. PubMed ID: 29168063
[TBL] [Abstract][Full Text] [Related]
4. HER2-Positive Breast Cancer: Association of MRI and Clinicopathologic Features With Tumor-Infiltrating Lymphocytes.
Lee HJ; Lee JE; Jeong WG; Ki SY; Park MH; Lee JS; Nah YK; Lim HS
AJR Am J Roentgenol; 2022 Feb; 218(2):258-269. PubMed ID: 34431365
[No Abstract] [Full Text] [Related]
5. Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies.
Hida AI; Sagara Y; Yotsumoto D; Kanemitsu S; Kawano J; Baba S; Rai Y; Oshiro Y; Aogi K; Sagara Y; Ohi Y
Breast Cancer Res Treat; 2016 Jul; 158(1):1-9. PubMed ID: 27260189
[TBL] [Abstract][Full Text] [Related]
6. Tumor-infiltrating lymphocytes status, programmed death-ligand 1 expression, and clinicopathological features of 41 cases of pure apocrine carcinoma of the breast: a retrospective study based on clinical pathological analysis and different immune statuses.
Xiao X; Jin S; Zhangyang G; Xiao S; Na F; Yue J
Gland Surg; 2022 Jun; 11(6):1037-1046. PubMed ID: 35800740
[TBL] [Abstract][Full Text] [Related]
7. Increased ERBB2 Gene Copy Numbers Reveal a Subset of Salivary Duct Carcinomas with High Densities of Tumor Infiltrating Lymphocytes and PD-L1 Expression.
Chatzopoulos K; Collins AR; Sotiriou S; Keeney MG; Visscher DW; Rivera M; Schembri-Wismayer DJ; Lewis JE; Greipp PT; Sukov WR; Chintakuntlawar AV; Price KA; Garcia JJ
Head Neck Pathol; 2020 Dec; 14(4):951-965. PubMed ID: 32350809
[TBL] [Abstract][Full Text] [Related]
8. Ductal carcinoma in situ of the breast: immune cell composition according to subtype.
Agahozo MC; van Bockstal MR; Groenendijk FH; van den Bosch TPP; Westenend PJ; van Deurzen CHM
Mod Pathol; 2020 Feb; 33(2):196-205. PubMed ID: 31375764
[TBL] [Abstract][Full Text] [Related]
9. Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer.
Ahn SG; Cha YJ; Bae SJ; Yoon C; Lee HW; Jeong J
BMC Cancer; 2018 Mar; 18(1):320. PubMed ID: 29573739
[TBL] [Abstract][Full Text] [Related]
10. Correlation between
Murakami W; Tozaki M; Sasaki M; Hida AI; Ohi Y; Kubota K; Sagara Y
Eur J Radiol; 2020 Feb; 123():108773. PubMed ID: 31918248
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negative operated breast cancers.
Fujimoto Y; Watanabe T; Hida AI; Higuchi T; Miyagawa Y; Ozawa H; Bun A; Fukui R; Sata A; Imamura M; Hirota S; Miyoshi Y
Breast Cancer; 2019 Nov; 26(6):738-747. PubMed ID: 31098866
[TBL] [Abstract][Full Text] [Related]
12. Distinct Tertiary Lymphoid Structure Associations and Their Prognostic Relevance in HER2 Positive and Negative Breast Cancers.
Liu X; Tsang JYS; Hlaing T; Hu J; Ni YB; Chan SK; Cheung SY; Tse GM
Oncologist; 2017 Nov; 22(11):1316-1324. PubMed ID: 28701569
[TBL] [Abstract][Full Text] [Related]
13. Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)-a translational analysis of the prospective WSG PlanB trial.
Kolberg-Liedtke C; Gluz O; Heinisch F; Feuerhake F; Kreipe H; Clemens M; Nuding B; Malter W; Reimer T; Wuerstlein R; Graeser M; Shak S; Nitz U; Kates R; Christgen M; Harbeck N
Breast Cancer Res; 2020 May; 22(1):47. PubMed ID: 32408905
[TBL] [Abstract][Full Text] [Related]
14. Two progressive pathways of microinvasive carcinoma: low-grade luminal pathway and high-grade HER2 pathway based on high tumour-infiltrating lymphocytes.
Morita M; Yamaguchi R; Tanaka M; Tse GM; Yamaguchi M; Otsuka H; Kanomata N; Minami S; Eguchi S; Yano H
J Clin Pathol; 2016 Oct; 69(10):890-8. PubMed ID: 27030304
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer molecular class ERBB2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFR.
Bhargava R; Beriwal S; Striebel JM; Dabbs DJ
Appl Immunohistochem Mol Morphol; 2010 Mar; 18(2):113-8. PubMed ID: 19801938
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Value of Tumor-Infiltrating Lymphocyte Density Assessed Using a Standardized Method Based on Molecular Subtypes and Adjuvant Chemotherapy in Invasive Breast Cancer.
Jang N; Kwon HJ; Park MH; Kang SH; Bae YK
Ann Surg Oncol; 2018 Apr; 25(4):937-946. PubMed ID: 29330719
[TBL] [Abstract][Full Text] [Related]
17. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
18. Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer.
Leon-Ferre RA; Polley MY; Liu H; Gilbert JA; Cafourek V; Hillman DW; Elkhanany A; Akinhanmi M; Lilyquist J; Thomas A; Negron V; Boughey JC; Liu MC; Ingle JN; Kalari KR; Couch FJ; Visscher DW; Goetz MP
Breast Cancer Res Treat; 2018 Jan; 167(1):89-99. PubMed ID: 28913760
[TBL] [Abstract][Full Text] [Related]
19. Quantitative digital image analysis of tumor-infiltrating lymphocytes in HER2-positive breast cancer.
Abe N; Matsumoto H; Takamatsu R; Tamaki K; Takigami N; Uehara K; Kamada Y; Tamaki N; Motonari T; Unesoko M; Nakada N; Zaha H; Yoshimi N
Virchows Arch; 2020 May; 476(5):701-709. PubMed ID: 31873876
[TBL] [Abstract][Full Text] [Related]
20. A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast Cancer.
Miglietta F; Ragazzi M; Fernandes B; Griguolo G; Massa D; Girardi F; Bottosso M; Bisagni A; Zarrilli G; Porra F; Iannaccone D; Dore L; Gaudio M; Santandrea G; Fassan M; Lo Mele M; De Sanctis R; Zambelli A; Bisagni G; Guarneri V; Dieci MV
Clin Cancer Res; 2023 Sep; 29(17):3429-3437. PubMed ID: 37417941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
